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This study was designed to determine if the
Amazonian medicinal sangre de grado, confers bene-
®t by suppressing the activation of sensory afferent
nerves. Methods: (i) vasorelaxation of rat mesenteric
arteries in response to calcitonin gene-related pep-
tide; (ii) rat paw edema in response to protease-
activating peptide receptor 2±activating peptide; (iii)
rat paw hyperalgesia in response to low-dose pro-
tease-activating peptide receptor 2±activating peptide
or prostaglandin E2; (iv) gastric hyperemia in
response luminal capsaicin; (v) a clinical trial of a
sangre de grado balm in pest control workers. The
parent botanical was fractionated for evaluation of
potential active components. In preconstricted rat
mesenteric arteries, highly diluted sangre de grado
(1:10,000) caused a shift to the right of the calcitonin
gene-related peptide dose±response curve (p < 0.01).
Paw edema in response to protease-activating pep-
tide receptor 2±activating peptide (500 mg) was
reduced by as single topical administration sangre de
grado balm (1% concentration, p < 0.01) for at least
6 h. Hyperalgesia induced by either low-dose pro-
tease-activating peptide receptor 2±activating peptide
(50 mg) or prostaglandin E2 was prevented by sangre
de grado balm. A fraction possessing analgesic and
capsaicin antagonistic properties was isolated and
high-performance liquid chromatography and gas
chromatography±mass spectrometry analysis indica-
ted that it was a proanthocyandin oligomer. In pest
control workers, sangre de grado balm (Zangrado)
was preferred over placebo, for the relief of itching,
pain, discomfort, edema, and redness in response to
wasps, ®re ants, mosquitoes, bees, cuts, abrasions,
and plant reactions. Subjects reported relief within
minutes. We conclude that sangre de grado is a
potent inhibitor of sensory afferent nerve mechan-
isms and supports its ethnomedical use for disorders
characterized by neurogenic in¯ammation. Key
words: capsaicin/Croton lechleri/itch, pain/sensory afferent
nerves. J Invest Dermatol 117:725±730, 2001
S
angre de grado (SdG), also known as Sangre de drago or
Dragon's blood, is a viscous, red tree sap that is used
extensively by indigenous cultures of the Amazon River
basin for its remarkable healing properties (Duke and
Vasquez, 1994; Jones, 1995; Phillipson, 1995). Derived
from several Croton species (C. dracanoides, C. palanostigma, C.
lechleri), SdG is common throughout Amazonia, with the highest
quality originating in the upper jungle of Peru and Ecuador. The
tree is fast growing, reaching heights of 30±45 ft (10±15 m) in 3 y.
Whereas the sap can be harvested like rubber, trees that are
repeatedly tapped are prone to fungal infections, thereby
diminishing productivity. Current experimental farming techniques
focus on growing and felling the trees in a 2±3 y cycle; at this time a
single tree will produce approximately 1.5 l of sap.
Mechanistically, little is known about SdG given the region and
cultures from which it originates. Applied to the skin for abrasions,
cuts, scratches, blisters, bites, and stings, SdG forms a long-standing
barrier possibly due to its ability to coprecipitate with proteins or
other matrix elements (Uchida et al, 1990). In so doing it is claimed
to foster accelerated wound healing and does so with reduced pain,
in¯ammation, and scarring (Vaisberg et al, 1989; Porras-Reyes et al,
1993; Chen et al, 1994).
SdG's applications in Amazonia are not limited to cutaneous
disorders. SdG is also taken orally, in dilute form, for severe
gastrointestinal distress, e.g., gastritis, gastric ulcer, intestinal
infections, and in¯ammation (Maxwell, 1990; Duke and Vasquez,
1994; Jones, 1995). In addition, because SdG has hemostatic
properties it is sometimes used to arrest excessive bleeding
associated with childbirth (this hemostatic effect is also useful for
severe cuts and lacerations). As this information is largely anecdotal,
the purpose of the present investigation was to evaluate the
mechanisms underlying the proposed ef®cacy of SdG in a
scienti®cally rigorous manner.
MATERIALS AND METHODS
Vasorelaxation of rat mesenteric arteries Mesenteric arteries were
removed from anesthetized 3 mo old female Fisher 344 rats (National
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Institutes of Aging) for the study of diameter changes, as previously
described by us (White et al, 1996). The small intestine was excised
immediately after sacri®ce of the rat and placed in ice-cold bicarbonate
buffer solution of the following composition (in mm): NaCl, 130; KCl,
4.7; MgSO4´7H2O, 1.17; KH2PO4, 1.18; NaHCO3, 14.9; dextrose, 5.5,
NaCa2EDTA, 0.03; CaCl2´2H2O, 1.6. Resistance-size arteries (3rd±4th
order branches of the superior mesenteric artery; approximately 250 mm
outer diameter) were cleaned of adherent fat and connective tissue and
cannulated at each end with glass microcannulae in an arteriograph
chamber. These arteries are located at the margin of the intestine, just
before the arteries branch and actually enter the intestinal wall. The
arteries were pressurized and maintained at 60 mmHg with a servo-
control device. Warm buffer (37°C) bubbled with a mixture of 95% O2,
5% CO2 was circulated through the arteriograph chamber at a rate of
20 ml per min.
All drugs and mediators were added to the superfusion solution. The
arteriograph was placed on the stage of an inverted microscope, and the
image of the artery projected on to a video monitor. The image of the
artery was continuously scanned and measurements of the outer diameter
stored in a computer ®le for analysis. Arteries were allowed to equilibrate
at 60 mmHg, in warmed, circulating buffer for a minimum of 45 min
prior to the initiation of the experimental protocol.
Arteries were constricted with an EC80 concentration of phenylephrine
(the concentration needed to produce 80% of the maximal contractile
response), and calcitonin gene-related peptide (CGRP) was added to the
superfusate bath at increasing concentrations until a full relaxation response
was achieved. The superfusate was washed, re-equilibrated and pheny-
lephrine was administered to raise vascular tone. SdG (1:10,000 dilution)
was added to the bath and the dose±response curve to CGRP repeated. In
a separate study, the CGRP alone administration was repeated without
coadministration of SdG. At the conclusion of the experiment, the bath
was rinsed, the vessel preconstricted and the vasodilator response to
acetylcholine evaluated as an example of a sensory afferent independent
vasodilator. Relaxations of arterial segments to CGRP are expressed as a
percentage of the phenylephrine-constricted diameter. Data were analyzed
using a nonlinear regression of sigmoidal dose±response curves (using
GraphPad Prism 2.01) from which an EC50 value (concentration of
CGRP that elicited 50% of the maximum response), maximum response
and slope. The negative logEC50 values (pD2) in the absence and presence
of SdG (1:10 000 dilution) were compared using a paired t test (Statistica,
Statsoft).
Rat paw edema Sprague±Dawley rats (250 g) were anesthetized with
sodium pentobarbitol. Twenty minutes prior to the intradermal injection
of protease activated receptor-2 activating peptide (PAR2-AP) (SLIGRL-
NH2, 500 mg) into the rat footpad, rats received either 40 mg of placebo
balm or balm containing SdG (1%, Zangrado Bug Bite Balm, Rainforest
Phytoceuticals, LLC, Delmar, NY, http://www.amazonmedicines.com)
topically to the footpad. This dose of PAR2-AP was chosen as based on
our previous experience that it elicits paw edema through neurogenic
mechanisms (Steinhoff et al, 2000). Basal paw volume was measured
before PAR2-AP administration, and every subsequent hour for a total of
6 h, as previously described (Vergnolle et al, 1999; Steinhoff et al, 2000).
Paw volume was measured using a hydroplethysmometer bath (Ugo
Basile, Italy) by an individual unaware of the treatment group.
Rat paw hyperalgesia
Induced by PAR2-AP Rats were treated in a manner similar to that
described above for paw edema studies except that the dose of PAR2-AP
was reduced to 50 mg (intradermal injection) to avoid complications
associated with edema formation. Rats were divided into two treatment
groups: (1) control, who received the placebo balm (devoid of SdG), and
(2) Zangrado balm (1% SdG). Both were delivered topically (40 mg)
15 min before intradermal administration of PAR2-AP. Paw withdrawal
latency time to a thermal stimulus, as determined in a Hargreave's
apparatus, was used as the index of pain sensitivity. This involves the
measurement of the time it takes for a rat to move (withdraw) its foot
away from a thermal stimulus (Vergnolle et al, 1999). Withdrawal times
were determined in each group prior to PAR2-AP administration (basal),
and then 30 and 60 min after PAR2-AP administration. A reduction in
latency withdrawal time is used as an index of hyperalgesia.
Induced by prostaglandin (PG) E2 Similarly to the experiments where
hyperalgesia was induced by PAR2-AP, paw hyperalgesia was also
induced by PGE2 (0.3 mg), administered by intradermal injection. Basal
withdrawal times were established and either placebo or Zangrado balm
containing 1% SdG were applied topically to the paw. Withdrawal times
were determined every 15 min over the course of 1 h, at which time
the PGE2 hyperalgesia response had returned to baseline.
Rat gastric hyperemia in response to capsaicin As previously
outlined (Gronbech and Lacy, 1996), gastric blood ¯ow was measured by
a laser Doppler ¯ow meter placed on the gastric luminal surface of
anesthetized, laparotomized rats. This involves the use of a plexiglass
chamber used for isolating the gastric mucosal surface whereas the
stomach remains fully innervated and with its blood supply intact. The
luminal surface is continually bathed in a buffered salt solution to which
capsaicin (320 mm), alone or with pretreatment with SdG (1% solution)
or SdG fractions. Hyperemia is expressed as a percentage change from
baseline.
SdG fractionation and structural analysis The SdG latex (30 ml)
was mixed with 270 ml of acetate buffer (1 mm sodium acetate, 1 mm
acetic acid, pH 4), vortexed and centrifuged at 1200 3 g for 3 min After
removal of the supernatant the precipitant was then mixed with
methanol (30 ml), vortexed, and centrifuged at 1200 3 g for 3 min. The
supernatant was applied to a C18 sephadex cartridge. Eluants were
collected with various water±methanol (0, 20, 40, 60, 80, and 100%)
washes and dried for analysis of biologic properties. Similarly, the super-
natant (20 ml) was also subjected to high pressure liquid chromatography
analysis. After ®ltration in a 20 mm ®lter, the supernatant components
were separated using a Varian Dynamax high pressure liquid chromato-
graphy system equipped with two Model SD-200 pumps, and a model
330 diode array detector, and a microsorb-MV C-18 reverse phase
column (25 3 0.46 cm) at a ¯ow rate of 1 ml per min. The mobile
phase was a gradient of 15±45% solvent A for 30 min, followed by an
increase to 88% solvent A, where solvent A is methanol, and solvent B is
0.1% acetic acid. Fractions were collected for biologic assay as well as
structural identi®cation of constituents by gas chromatography±mass
spectroscopy and 1H nuclear magnetic resonance.
Clinical evaluation in pest control workers Terminex pest control
workers were invited to participate in a placebo-controlled trial. Either a
balm containing SdG (1%, Zangrado Bug Bite Balm, Rainforest
Phytoceuticals, LLC; http://www.amazonmedicines.com) or placebo
(balm base without the SdG) was applied to various skin conditions
encountered over a 3 mo period at the discretion of the participants.
The balms were coded and their nature was not disclosed to the
participants during the study. Because of their occupation, these pest
control workers incur various cutaneous af¯ictions. Participants were also
asked to keep a log of the type of af¯ictions, associated symptoms, time
to achieve relief, complications or side-effects, and whether reapplication
was necessary. A total of 11 participants were enrolled but only 10
participated in the study. The time frame was open-ended, but was
concluded after 3 mo because the spring infestations had yielded a
reasonable number of ``events''. Because of the random nature of these
af¯ictions in a ``real world'' situation, participants were asked to apply
either balm at their discretion. If for example, more than one bite
occurred at any one time then participants were asked to apply both
balms on different locations in order to facilitate comparison. Some
events by their nature were isolated, however, and so balms were applied
in series as opposed to in parallel. At the conclusion of the trial logged
information was decoded and analyzed. No workers were encouraged to
be attacked by insects, rather all ``events'' occurred as a hazard of their
occupation.
RESULTS
CGRP vasorelaxation Rat mesenteric arteries, preconstricted
with phenylephrine, relaxed in response to addition of CGRP to
the superfusate (pD2 = 8.84 6 0.08, n = 5). Addition of SdG to
the superfusate at a dilution of 1:10 000 resulted in a signi®cant shift
of the dose±response curve to the right (pD2 = 8.08 6 0.1; n = 5,
p < 0.01), as indicated in Fig 1. Vasorelaxant responses to acetyl-
choline were unaltered by SdG (data not shown). Repetitive dose±
response curves to CGRP in the absence of SdG were identical.
Rat paw edema Edema induced by intradermal injection of
PAR2-AP is the result of sensory afferent nerve activation, as this
response can be abolished by neonatal capsaicin treatment (sensory
afferent ablation), and neurokinin receptor antagonism (Vergnolle
et al, 1999; Steinhoff et al, 2000). To address the potential effects of
SdG, we applied a balm containing 1% SdG to the rat paw 20 min
prior to PAR2-AP injection, with edema monitored for a
subsequent 6 h (Fig 2, n = 8 in each group). In both groups
PAR2-AP caused a marked increase in paw volume by 1 h,
indicative of edema development. Paw volume then slowly
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declined over the next 5 h in the placebo group. In SdG-treated
paws, the decline in paw volume was more dramatic and sustained
despite its single topical application, resulting in approximately 50%
less edema (p < 0.01, Fig 2).
Rat paw hyperalgesia Intradermal injection of PAR2-AP
resulted in a decrease in the latency withdrawal period to a heat
source (Fig 3). This is indicative of a hyperalgesic state.
Pretreatment with topical SdG (1%, Zangrado Bug Bite Balm)
prevented the induction of hyperalgesia, with the latency
withdrawal time remaining at its baseline level despite PAR2-AP
administration (Fig 3). Zangrado balm did not affect withdrawal
latency time in rats that did not receive PAR2-AP (data not shown)
indicating that it was not acting as an anesthetic. Hyperalgesia was
also induced by intradermal PGE2, which is thought to induce an
increased sensitivity to pain perception by raising the resting
potential of sensory afferent nerve ®bers. In these experiments
intradermal PGE2 resulted in a signi®cant reduction in paw
withdrawal time (Fig 4) and this effect was blocked by a single
topical administration of SdG balm.
Potential thermal analgesic bioactivity of fractionated SdG was
assessed using PAR2-AP as the algesic agent. Two fractions of SdG
were ineffective (fractions 2 and 3), with paw withdrawal times
being indistinguishable from vehicle-treated animals (Fig 5). In
contrast, fraction 5 was fully effective in preventing the hyperalgesic
response to intradermal PAR2-AP, comparable with that observed
with the parent botanical SdG (Fig 3).
Capsaicin-induced hyperemia Gastric hyperemia in response
to luminal capsaicin (320 mm) was evident in control animals, with
an average increase in basal blood ¯ow of 60% (Fig 6). In rats
treated with either SdG or its derivative, fraction 5, this capsaicin-
induced hyperemia response was largely abolished (p < 0.01). The
concentration chosen for assessment, 1%, was based on the
concentration that was effective topically in rat edema and
analgesic assays as well as the clinical evaluation in pest control
workers.
Structural determination of active chemical con-
stituents Analysis of fraction 5, a fraction that shared the same
biologic properties of the parent botanical, indicated that it was a
pure compound with a molecular weight of 930, and likely to
be an oligomer of proanthocyandins. Proanthocyandins are the
predominant chemical component of SdG but yet, to date,
proanthocyandins have not been reported to possess sensory
afferent nerve suppressant activity. It should be noted that
fraction 3, which was ineffective as an analgesic agent (Fig 5),
possessed the same molecular weight and proanthocyandin
Figure 2. SdG and PAR-2AP induced Edema Formation.
PAR-2AP used was SLIGRL-NH2. It was injected into the rat paw at a
dose of 500 mg. Either the placebo balm (closed circles, solid lines) or the
Zangrado Bug Bite Balm (open circles, broken lines) were applied topically
(40 mg) to the paw 20 min prior to injection of the SLIGRL-NH2. Paw
volume was measured using a hydroplethysmometer, by an individual
unaware of the treatments the rats had received. Results depict the
mean 6 SEM for eight rats in each group. The asterisk indicates a
signi®cant difference (p < 0.05) between placebo and Zangrado balm
groups as determined by ANOVA and post hoc analysis with Student±
Newman±Keuls t test.
Figure 3. Hyperalgesia induced by PAR-2AP and the effects of
SdG. Intradermal injection of PAR-2AP (50 mg) resulted in a state of
hyperalgesia as indicated by a reduction in latency withdrawal time from
baseline in rats treated with placebo balm (* p < 0.05 compared with
basal values, n = 5, ANOVA and post hoc analysis with Dunnett's multiple
comparison test). Zangrado balm (containing 1% SdG, n = 7) completely
prevented the induction of hyperalgesia, with withdrawal latency being
unaltered from baseline. Results are depicted as mean 6 SEM.
Figure 1. SdG and CGRP-induced vascular relaxation. Dose±
response curves to CGRP in rat mesenteric arteries preconstricted with
phenylephrine (PE). Data are expressed as a percentage of the PE tone.
Vascular preparations were made from ®ve animals in each group.
Sequential dose±response curves to CGRP were superimposable (closed
circles, data not shown). After establishing the response to CGRP alone
SdG (1:10,000 dilution) was introduced into the superfusate, and the
response to CGRP repeated. SdG caused a signi®cant shift of the dose±
response curve to the right (open circles, broken lines, p < 0.05). Results
are depicted as mean 6 SEM for ®ve animals in each group.
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oligomer base as fraction 5. In other words, it appears that only
certain isomers of these proanthocyandin oligomers possess the
desired activity, with some proanthocyandin isomers (fraction 3)
having no analgesic activity, whereas others (fraction 5) display
both analgesic and capsaicin antagonistic properties. At this time
further comparative analysis of how the spatial arrangement of these
complex oligomers is not available. Given the complex nature of
the components of this botanical it should be noted that chemical
constituents other than proanthocyandins may be active.
Clinical evaluation of a SdG-based balm An evaluation of a
commercially available SdG balm (Zangrado Bug Bite Balm) for
relief of the symptoms of insect bites, stings, and other skin
conditions was done in Terminex pest control workers in New
Orleans, LA. These workers are prone to these hazards as part of
their occupation. Participants compared the effects of a placebo
balm with a balm containing 1% SdG over a 3 mo period. As noted
in Table I, the primary af¯iction during this period was ®re ant
bites, with all participants suffering at least one attack. Fire ants are
endemic throughout the south-eastern United States, and they
elicit an initial painful bite followed by an itching response that can
persist for weeks. Because of the uncontrolled environment in
which this study was performed every participant did not
experience the same number or type of encounters. Some
individuals encountered the same af¯iction multiple times (for
example ®re ants).
Figure 5. Effects of SdG fractions on the hyperalgesia induced by
PAR2-AP. Intradermal injection of PAR2-AP (50 mg) resulted in the
induction of thermal hyperalgesia as indicated by a reduction in latency
withdrawal time from baseline in rats treated topically with the vehicle
balm. Balm containing 1% of fractions 2, 3, or 5 isolated from the parent
botanical, SdG, were evaluated at 30 and 60 min after PAR2-AP
administration. Fraction 5 completely prevented the induction of
hyperalgesia, with withdrawal latency being indistinguishable from
baseline. In contrast, fractions 2 and 3 were ineffective analgesic agents,
producing similar results to the vehicle control. Results are depicted as
mean 6 SEM, n = 5 (*p < 0.05 compared with basal values, n = 5,
ANOVA and post hoc analysis with Dunnett's multiple comparison test).
Figure 6. Effects of SdG and fraction 5 on the gastric hyperemia
induced by luminal capsaicin. Gastric mucosal blood ¯ow was
measured by a laser Doppler ¯ow meter in rats. Luminal exposure to
capsaicin (320 mm) greatly increased mucosal blood ¯ow (expressed as a
percentage change from baseline, mean 6 SEM). in rats pretreated with
luminal SdG or fraction 5 (both 1% solutions), the hyperemic response
to capsaicin was largely absent (n = 5, *p < 0.01 vs vehicle).
Table I. Af¯ictions experienced by pest control workersa
Af¯iction
Individuals reporting
a speci®c af¯iction
Total no. of
individuals enrolled
Bee 1 10
Wasps 6 10
Mosquito 1 10
Fire ant 10 10
Other ants 6 10
Plant reactions 1 10
Cut 5 10
Abrasion 1 10
aThe number of individuals reporting an individual af¯iction is noted. Not all
participants encountered the same pro®le of af¯ictions, as to be expected, as these
events were random and re¯ect the occupational hazard. It is important to note
that an individual participant may have experienced the same type of af¯iction
multiple times, but it is only noted here once. This table only describes the pro®le
of events that were recorded over a 3 mo period, and not the number of events
that any single participant encountered.
Figure 4. Hyperalgesia induced by PGE2 and the effects of SdG.
Intradermal injection of PGE2 (0.3 mg) resulted in a state of hyperalgesia
as indicated by a reduction in latency withdrawal time from baseline in
rats treated with placebo balm (*p < 0.05 compared with basal values,
n = 5, ANOVA and post hoc analysis with Dunnett's multiple comparison
test). Zangrado balm (containing 1% SdG, n = 5) completely prevented
the induction of hyperalgesia, with withdrawal latency being unaltered
from baseline. Results are depicted as mean 6 SEM.
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The symptoms associated with these encounters are recorded in
Table II. Itching (10 of 10 participants) was the predominant
symptom, re¯ecting the preponderance of ®re ant bites among the
workers. The placebo balm offered relief in only two cases, whereas
the SdG relieved symptoms in all individuals, for all applications.
The SdG balm was preferred over placebo balm by all participants
and relief was reported to occur in less than 2 min, on average. The
diversity of conditions in which the SdG offered symptomatic relief
was broad (Table I). That combined with the speed by which it
achieved relief, is highly suggestive that bene®t was related to a
sensory afferent-based mechanism of action.
DISCUSSION
Despite the widespread use of SdG in Amazonia as an analgesic,
antidiarrheal, and wound-healing agent few in the Western world
are aware of its existence and little is known about how it achieves
these therapeutic bene®ts. We postulated that these bene®ts may
result from a suppression of sensory afferent nerve activation and
the present results support this conclusion. This hypothesis was
generated from experience and the knowledge that sensory afferent
nerves serve as broad-based sentinels in the skin, gut, and lung, and
that the rapidity by which SdG relieved pain and itching was
consistent with a neurogenic mechanism. In addition, the
serendipitous personal observation by an author that SdG relieved
the symptoms of cutaneous capsaicin (sensations associated with an
overly spicy meal) focused our attention to sensory afferent nerve
mechanisms.
SdG appears to suppress the activation of sensory afferent nerves
at a prejunctional level, in addition to inhibiting the tissue responses
to CGRP, a primary neurotransmitter of sensory afferent nerves.
Supporting the present ®ndings we recently noted that SdG was
able to attenuate the epithelial secretory response to capsaicin but
not the neurokinin-1 antagonist, Sar-Met-substance P in Ussing
chambers of guinea pig ileum (Miller et al, 2000). The use of guinea
pig ileum in this study offered signi®cant advantages for evaluating
sensory afferent nerve mechanisms. Speci®cally, capsaicin-induced
epithelial secretion is due solely to the release of substance P and
subsequent activation of NK-1 receptors (Vanner and
MacNaughton, 1995). Thus, as SdG did not alter NK-1 secretory
responses but attenuated capsaicin-induced secretion, we can
conclude SdG was operating at a prejunctional level, directly
blocking the activation of sensory afferent nerves (Miller et al,
2000). This ability of SdG to block capsaicin epithelial secretory
responses was extended in our study to include capsaicin-induced
gastric mucosal vasodilation (Fig 6).
The conclusion that SdG is an inhibitor of sensory afferent nerve
mechanisms is further supported by our studies using PAR2-AP or
PGE2 as the hyperalgesic agents. A dose of PAR2-AP (50 mg per
kg) that does not elicit edema was used to avoid the complications
of interpretation surrounding the potential anti-in¯ammatory
actions of SdG in¯uencing pain perception. Topical SdG in this
setting completely prevented the hyperalgesia induced by PAR2-
AP (Vergnolle, 2000). PAR2-AP has only recently been described
as a means of direct activation of sensory afferent nerves (Steinhoff
et al, 2000) and its precise mechanism is less well characterized than
capsaicin.
Hyperalgesia induced by PGE2 was also blocked by topical SdG.
In contrast to PAR2-AP, PGE2 elicits hyperalgesia by indirect
means, speci®cally PGE2 sensitizes sensory afferent nerves to
activation by other stimuli, but yet does not directly activate these
nerves. From this collage of results we conclude that SdG is acting
in a broad manner to suppress sensory afferent nerve activation.
Whereas it is possible that SdG is acting as an antagonist for PAR2-
AP, this cannot explain its ability to block PGE2 or capsaicin
responses. The capsaicin or vanilloid receptor is thought to be a
critical pathway for thermal hyperalgesia to various stimuli, as
indicated by the absence of thermal hyperalgesia in mice with
vanilloid receptor 1 (VR1) gene deletions (Caterina et al, 2000;
Davis et al, 2000). Sterner and Szallasi (1999) noted that current
medicinal plants invariably possess residual VR1 agonistic activity,
termed pungency. This is not a problem noted with SdG as it did
not raise basal gastric blood ¯ow nor is it pungent to the taste.
Whereas one explanation for the present observations is that SdG
acts as a pure VR 1 antagonist with no agonist properties, there is
no direct support for that conclusion, and alternative indirect
pathways leading to sensory afferent nerve suppression must be
considered.
It is interesting to note that SdG was an effective analgesic and
anti-in¯ammatory agent when applied topically, even when the
hyperalgesic stimuli were applied by intradermal injection. This
suggests that active components have suf®cient lipophilicity to
readily cross the skin. From the observations from the pest control
workers who noted symptomatic relief in less than 2 min, this
transcutaneous absorption appears to be rapid. Fractionation studies
indicated that fraction 5, which was an effective inhibitor of
capsaicin-induced hyperemia, was an analgesic agent when applied
topically. Whereas capsaicin-induced tissue responses may not
always be neuronal in origin (Wallengren and HaÊkanson, 1987;
Wallengren and HaÊkanson, 1992), the pattern and rapidity of SdG
effects suggest that a neuronal action is likely.
Whereas it is generally recognized that medicinal plants exert
their effects through a combination of chemical constituents we
have attempted to isolate the active components in this natural
product. Antioxidant oligomers of proanthocyandins have been
reported to mediate the ability of SdG to attenuate epithelial
secretion in response to increased epithelial levels of cyclic
adenosine monophosphate and also as an inhibitor of viral
replication (Ubillas et al, 1994; Gabriel et al, 1999). Proantho-
cyandins constitute the major chemical class in SdG, accounting for
90% of its composition. Proanthocyandins, however, are common
components of numerous plants, e.g., they are responsible for
giving red wine its characteristic color, a property shared with SdG.
Wine-derived proanthocyandins have not been reported to block
sensory afferent nerve activation, suggesting that either the
proanthocyandins in SdG differ from other sources or other
components are more important. A preliminary structural evalu-
ation of active principles indicates that certain proanthocyandin
oligomers may underlie the desired effects. One fraction, tenta-
tively identi®ed as a proanthocyandin oligomer with a molecular
weight of 930, was analgesic and attenuated capsaicin responses
in vivo; however, related oligomers with an identical molecular
weight were devoid of analgesic activities. This paradoxical result
suggests that the manner in which these complex oligomers are
spatially arranged is critical for their biologic activity. The nature of
this arrangement is yet to be determined. One must also consider
that bioactivity lies in alternative chemical classes (Pieters et al,
1993).
The dual prejunctional and postjunctional effects of SdG on
sensory afferent mechanisms (nerve activation and CGRP receptor
Table II. Pro®le of symptoms experienced by pest control
workers and effects of placebo vs SdG (Zangrado) balma
Symptoms
Individuals
reporting
Relieved by
placebo
Relieved by
Zangrado
Preference
(%)
Itching 10/10 0 10*** Zangrado (100)
Pain 5/10 1 5* Zangrado (100)
Redness 6/10 1 6* Zangrado (100)
Swelling 6/10 0 6** Zangrado (100)
Discomfort 4/10 0 4* Zangrado (100)
aThe pro®le of symptoms was dependent upon the type of af¯iction that these
workers encountered. For example, all participants were bitten by ®re ants during
the study and the primary symptom associated with ®re ant bites is intense itching.
Comparisons between placebo and Zangrado balms were performed using the
Fishers Exact test (*p < 0.05; **p < 0.01; ***p < 0.001). All participants prefer-
red the Zangrado balm over the placebo balm for symptomatic relief; on average
relief was reported to occur in < 2 min.
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inhibition) are unique and are consistent with both the rapidity and
breadth of SdG's bene®ts. Combined with its reported antimicro-
bial (Rao et al, 1982; Chen et al, 1994; Phillipson, 1995) and
antiviral properties (Ubillas et al, 1994) it is timely to note that it is
unlikely that no single chemical would share all these functions.
SdG may be an example of how a natural product through its
chemical diversity, may offer therapeutic advantages over a
pharmaceutical. In the speci®c case of managing neurogenic
in¯ammation the current approach is to treat with other
phytochemical vanilloids, such as capsaicin or resiniferatoxin. The
goal of this approach is to deplete the sensory afferent nerve
terminals of neurotransmitters in order to limit their contribution to
both the pain signal and the local tissue responses. This result is
achieved, however, by the acute activation of the precise
mechanisms that one is trying to block, and is in essence a clumsy
approach to therapy. A more speci®c approach, however, has not
been available. SdG offers a different approach to managing
disorders characterized by excessive or sustained activation of
sensory afferent nerves (neurogenic in¯ammation) ± rapid suppres-
sion of nerve activation. Conditions in which SdG may offer new
therapeutic options include eczema, psoriasis, contact dermatitis
and hypersensitivity reactions and ultraviolet damage (Goebeler
et al, 1994; Ansel et al, 1996; Wallengren, 1997; Quinlan et al,
1998; Scholzen et al, 1999). Potentially any skin condition
characterized by itching, pain, edema, redness, and discomfort
may receive bene®t from an agent that inhibits sensory nerve
afferent activity.
Ethnomedical applications for SdG are not con®ned to the skin
(Maxwell, 1990). The oral intake of SdG for diarrhea and intestinal
distress may well be due to its ability to modify sensory afferent
mechanisms in the gut (Miller et al, 2000). Sensory afferent nerves
are major components of the enteric nervous system, and
contribute not only to secretion, but also to cramping, discomfort,
and pain perception. One may speculate that SdG could also
provide therapeutic bene®t for various pulmonary disorders that
involve sensory afferent nerves. These include airway hyperrespon-
siveness ± cough, asthma (Reidel et al, 1997; Choi and Kwon,
1998; Tohda et al, 1998), and viral infections (Piedimonte et al,
1990, 1997; Yamawaki et al, 1995), provided an adequate delivery
system could be designed. In addition, sensory afferent nerves and
their neuropeptides have also implicated in the pathogenesis of
arthritis (McDougall et al, 1999; Vilensky and Cook, 1998)
We conclude that SdG offers a valuable tool for determining the
role of sensory afferent nerves in in¯ammation. Considering the
recent advances provided by studies of the VR1 knock-out mice,
demonstrating signi®cant thermal analgesia resulting from the
failure to activate sensory afferent nerves (Caterina et al, 2000;
Davis et al, 2000), any botanical that suppresses sensory nerve
activity warrants a detailed evaluation of its therapeutic potential.
Indeed, SdG's actions as an analgesic and anti-in¯ammatory agent
may provide a new and valuable therapeutic approach to a variety
of in¯ammatory disorders and serves to highlight the valuable
medicinal resources that are still contained within the rain forests of
Amazonia.
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